745 related articles for article (PubMed ID: 33412224)
1. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells.
Valla S; Hassan N; Vitale DL; Madanes D; Spinelli FM; Teixeira FCOB; Greve B; Espinoza-Sánchez NA; Cristina C; Alaniz L; Götte M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070901
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
5. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
[TBL] [Abstract][Full Text] [Related]
7. Tailored-CuO-nanowire decorated with folic acid mediated coupling of the mitochondrial-ROS generation and miR425-PTEN axis in furnishing potent anti-cancer activity in human triple negative breast carcinoma cells.
Ahir M; Bhattacharya S; Karmakar S; Mukhopadhyay A; Mukherjee S; Ghosh S; Chattopadhyay S; Patra P; Adhikary A
Biomaterials; 2016 Jan; 76():115-32. PubMed ID: 26520043
[TBL] [Abstract][Full Text] [Related]
8. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
9. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
10. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
13. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
14. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
15. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
17. Folic-Acid-Adorned PEGylated Graphene Oxide Interferes with the Cell Migration of Triple Negative Breast Cancer Cell Line, MDAMB-231 by Targeting miR-21/PTEN Axis through NFκB.
Basu A; Upadhyay P; Ghosh A; Chattopadhyay D; Adhikary A
ACS Biomater Sci Eng; 2019 Jan; 5(1):373-389. PubMed ID: 33405856
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
19. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
20. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
